VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Stock Performance

Shares of NYSE:VNRX opened at $0.57 on Wednesday. The company has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.71. The company has a market capitalization of $52.50 million, a PE ratio of -1.24 and a beta of 1.12. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23.

VolitionRx (NYSE:VNRX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.34 million. On average, sell-side analysts forecast that VolitionRx will post -0.31 earnings per share for the current year.

Insider Activity

In other VolitionRx news, Director Guy Archibald Innes purchased 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was acquired at an average price of $0.67 per share, with a total value of $100,500.00. Following the acquisition, the director now directly owns 406,683 shares of the company’s stock, valued at approximately $272,477.61. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.80% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.